4 July 2018 - Erleada decreased the risk of metastasis or death in patients by 70% and improved median metastasis-free survival by more than two years.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has approved Erleada (apalutamide tablets), an oral treatment for patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Erleada was granted priority review status by Health Canada and is the first treatment approved for men diagnosed with nmCRPC.

Health Canada's approval of Erleada is based on Phase 3 data from the SPARTAN clinical trial, which showed Erleada decreased the risk of metastasis or death in nmCRPC patients by 70% and improved median metastasis-free survival by more than two years (difference of 24.8 months) compared to placebo.

Read Janssen press release